NSI-566 Archives | Be Korea-savvy
Neuralstem’s NSI-566 Stem Cell Therapy Confers Neurological Improvement in Spinal Cord Injury Patients with Complete Paraplegia

Neuralstem’s NSI-566 Stem Cell Therapy Confers Neurological Improvement in Spinal Cord Injury Patients with Complete Paraplegia

GERMANTOWN, Md., Jun. 4 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the results from a study published in the journal Cell Stem Cell that support the potential of transplanted NSI-566, a human spinal cord-derived neural stem cell line (HSSC) to benefit patients with chronic [...]

Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury

Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury

GERMANTOWN, Md., Apr. 10 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced that it completed the first surgery in the second, cervical injury cohort of a Phase 1 clinical trial in patients with chronic spinal cord injury [...]

Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury

Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury

GERMANTOWN, Md., Mar. 13 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, highlighted the publication of a manuscript in Nature Medicine showing that NSI-566, Neuralstem’s lead cell therapy candidate, provided meaningful improvement in forelimb function in a non-human primate model of acute spinal cord injury. [...]

Neuralstem to Participate at Cell and Gene Therapy World

Neuralstem to Participate at Cell and Gene Therapy World

GERMANTOWN, Md., Jan. 22 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief Scientific Officer of Neuralstem, will discuss NSI-566, the Company’s stem cell therapy program, at the Cell and Gene Therapy World at the Hyatt Regency in Miami, FL.  The presentation [...]